The disclosure pertains to a strontium-90 sealed radiological or radioactive source, such as may be used with treatment of the eye or other medical or industrial processes. The sealed radiological source includes a radiological insert within an encapsulation. The encapsulation may include increased shielding in the center thereof.

The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.

A flexible or elastic brachytherapy strand that includes an imaging marker and/or a therapeutic, diagnostic or prophylactic agent such as a drug in a biocompatible carrier that can be delivered to a subject upon implantation into the subject through the bore of a brachytherapy implantation needle has been developed. Strands can be formed as chains or continuous arrays of seeds up to 50 centimeters or more, with or without spacer material, flaccid, rigid, or flexible.

A dual double balloon catheter includes a catheter having a proximal end portion, a central portion and a distal end portion. The catheter includes a plurality of lumens within the catheter extending from the proximal end portion, and a plurality of inflatable balloons positioned in the central portion and/or the distal end portion, and the balloons being communicatively connected with a corresponding one of the plurality of lumens to selectively inflate/deflate the corresponding inflatable balloon, wherein one or more of inflatable balloons further includes a second one of the plurality lumens associated with a corresponding inner wall of a corresponding inflatable balloon and adapted to receive a radioactive dose or a therapeutic agent for a treatment. The plurality of balloons can have varying sizes in relation to each other and also include lumens within or associated with the inner walls of the balloons to deliver a treatment.

This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.

An implantable system is disclosed that includes an encapsulated housing including a radioactive source. The encapsulated housing is internally coated with a light-generating coating that converts the radioactive energy to light, that is then output in vivo to a photodiode positioned proximate to at least part of the encapsulated housing in vivo. The photodiode is configured to generate electrical current from the light, which electrical current is output to a power conditioning circuit that is configured to use the electrical current as an input electrical current and to output power to a load in vivo. The encapsulated may also be internally coated, at least in part, with a light directing coating that causes light to be directed toward an optical lens that focuses the light on the photodiode. The radioactive source may be a gas having a low half-life and which poses no health risk to a patient if released.

Embodiments of the present disclosure are directed to a phototherapy eye device. In an example, the phototherapy eye device includes a number of radioluminescent light sources and an anchor. Each radioluminescent light source includes an interior chamber coated with phosphor material, such as zinc sulfide, and containing a radioisotope material, such as gaseous tritium. The volume, shape, phosphor material, and radioisotope material are selected for emission of light at a particular wavelength and delivering a particular irradiance on the retina (when implanted in an eyeball). The wavelength is in the range of 400 to 600 nm and the irradiance is substantially 10.sup.9 to 10.sup.11 photons per second per cm.sup.2.

The invention relates to a radiolabelled material comprising a polymer, a radioactive isotope, and an immobilizing agent, wherein the immobilizing agent is capable of immobilizing the radioactive isotope on or in the polymer, and wherein the immobilizing agent is a macromolecule comprising a polycation with multiple pendant metal-chelating side-chains. The invention also relates to a process for making a radiolabelled material, to use of a radiolabelled material for the preparation of medicaments for treating cancer and/or for radiation imaging and to use of a radiolabelled material in the treatment of cancer. There is further described use of an immobilizing agent to immobilize a radioactive isotope on or in a polymer.

A nuclear medicine infusion system (10) may be used to generate and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the infusion system includes a frame (30) that carries a radioisotope generator (52) that generates radioactive eluate via elution. The frame may also carry a beta detector (58) and a gamma detector (60). The beta detector can be positioned to measure beta emissions emitted from the radioactive eluate supplied by the generator. The gamma detector can be positioned to measure gamma emissions emitted from a portion of the radioactive eluate to evaluate a safety of the radioactive eluate delivered by the infusion system.

An infusion system may include a strontium-rubidium radioisotope generator that generates a radioactive eluate via elution, a beta detector, a gamma detector, and a controller. The beta detector and the gamma detector may be positioned to measure beta emissions and gamma emissions, respectively, emitted from the radioactive eluate. In some examples, the controller is configured to determine an activity of rubidium in the radioactive eluate based on the beta emissions measured by the beta detector and determine an activity of strontium in the radioactive eluate based on the gamma emissions measured by the gamma detector.